Table 2.
Reports of changes in lncRNA expression in laboratory models and patients with MI.
| LncRNA | Expression | Target | Mechanism | Model (In vitro, in vivo, human) | Tissue, blood, cell | References |
|---|---|---|---|---|---|---|
| SARRAH | Down | NRF2, GPC6, PDE3A, ITPR2, PARP8, SSBP2 | Decrease apoptosis | In vitro, in vivo | Tissue | (172) |
| SENCR | Down | miR-1 | Alleviated apoptosis and inflammatory response | Human, in vitro | Blood | (153) |
| CARL | Down | miR-539 | Suppressed mitochondrial fission and apoptosis | In vivo, in vitro | Tissue | (173) |
| NONMMUT036355, NONMMUT003691, NONMMUT034297, NONMMUT073076, KnowTID_00004703 | Down | – | – | In vivo | Tissue | (174) |
| CAIF | Down | p53 | Suppressed autophagy | In vivo, in vitro | Tissue | (175) |
| Dancr | Down | miR-6324 | Inhibited apoptosis, enhanced autophagy | In vitro | H9c2 cell line | (176) |
| UCA1 | Down | miR-128 | Alleviated autophagy | In vivo, in vitro | Tissue | (177) |
| UCA1 | Down | miR-128 | Alleviated autophagy | In vivo, in vitro | Tissue | (177) |
| UCA1 | Down | miR-128 | Alleviated autophagy | In vivo, in vitro | Tissue | (177) |
| FAF | Down | FGF9 | Inhibited apoptosis | In vivo, in vitro | Tissue, cardiomyocytes | (178) |
| N1LR | Down | TGF-β1, Col1a1, Col3a1, α-SMA | Alleviated apoptosis, inflammation reaction and fibrosis | In vitro, in vivo | Tissue, H9c2 cell line | (179) |
| NR_047662.2, uc002ddj.1 | Down | – | – | Human | Blood | (180) |
| MIRT1, MIRT2 | Up | – | – | In vivo | Tissue | (181) |
| NONMMUT013316, NONMMUT030245, NONMMUT065582, KnowTID_00006395 | Up | – | – | In vivo | Tissue | (174) |
| NONMMUT022554 | Up | PI3K-Akt | – | In vivo | Tissue | (174) |
| NONMMUT023529, NONMMUT022555, NONMMUT72211, KnowTID_00006493 | Up | – | – | In vivo | Tissue | (174) |
| TUG1 | Up | miR-142-3p | Increased apoptosis and autophagy | In vivo, in vitro | Tissue | (182) |
| PVT1 | Up | miR-186 | Increased apoptosis and autophagy | In vitro | AC16 cells | (156) |
| NEAT1 | Up | miR-378a-3p | Promoted cell proliferation and migration, regulated expression of autophagic factors | In vivo, in vitro, human | Tissue, blood | (183) |
| TTTY15 | Up | miR-374a-5p | Suppressed autophagy | In vivo, in vitro | Tissue, H9c2 and HL-1 cells | (160) |
| HRIM | Up | – | Suppressed autophagy | In vivo, in vitro | Tissue, H9c2 cell line | (184) |
| AK088388 | Up | miR-30a | Promoted autophagy | In vitro | HL-1 cell line | (185) |
| FOXD3-AS1 | Up | NF-κB | Enhanced apoptosis and autophagy | In vitro | H9c2 cell line | (186) |
| AK139328 | Up | miR-204-3p | Promoted autophagy | In vivo, in vitro | Tissue, cardiomyocyte | (187) |
| MHRT | Up | – | Decreased apoptosis | In vitro, human | Blood, cardiomyocytes | (188) |
| NRF | Up | miR-873 | Increased necrosis | In vitro, in vivo | Tissue, cardiomyocytes | (109) |
| THRIL | Up | miR-99a | Decreased cell viability, migration and invasion, increased apoptosis | In vitro | H9c2 cell line | (189) |
| XIST | Up | miR-150-5p | Inhibited apoptosis | In vitro | H9c2 cell line | (150) |
| TTTY15 | Up | miR-455-5p | Decreased cell migration and invasion, increased apoptosis | In vitro | HCMs | (158) |
| NONMMUT032513, NONMMUT074571 | Up | ZEB1 | – | In vivo | Tissue | (190) |
| ENST00000581794.1, ENST00000509938.1 | Up | – | – | Human | Blood | (180) |